Concentration

2

Review clinical trials related to Concentration. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Not yet recruiting

Effects of Ropivacaine Concentrations on Prolonged Labor Analgesia

With the changes in medical models and improvements in people's quality of life, parturients have higher demands for childbirth, making the alleviation and elimination of labor pain an important aspect of modern obstetrics. Intrathecal labor analgesia has been widely adopted in clinical practice to relieve pain. However, current studies mainly focus on parturients who are just beginning to receive labor analgesia, while for those experiencing prolonged analgesia, medical institutions still use traditional formulations, lacking relevant guidelines or expert consensus. In such cases, prolonged waiting and anxiety may lower the pain tolerance of parturients, leading to an increased need for higher concentrations of local anesthetics. To address this clinical gap, this study aims to explore the effects of different concentrations of ropivacaine in prolonged labor analgesia and has designed a prospective randomized controlled trial (RCT) to provide evidence for improving the analgesic regimen for this group of parturients.

Participants needed: 100
Trial details
Age: 18+Biological sex: FemaleType: InterventionalSponsor: Chengdu Jinjiang Maternity and Child Health HospitalUpdated: Jun 6, 2025Locations: 1
Eligibility criteria

ASA II [+4]

Contraindications for epidural labor analgesia [+4]

Status: Recruiting

A Clinical Trial to Assess Cognitive Effects of Cognitive Nutritional Supplement in General Population

This is a double-blind, randomized, 12-week parallel study that aims to determine the effects of a cognitive nutritional supplement for 12 weeks on cognition parameters specific to attention/focus related domains, compared to a placebo control, in a general population of adult men and women in the United States.

Participants needed: 422
Trial details
Age: 25-65Biological sex: AllType: InterventionalSponsor: Pharmavite LLCUpdated: Apr 15, 2025Locations: 1
Eligibility criteria

Male or female, ≥25 to ≤65 years of age at screening. [+9]

Diagnosed neurological disorder such as Alzheimer's disease, Parkinson's disease... [+23]